Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report

MET exon 14 skipping mutation (METex14m) is rare and occurs in approximately 1-4% of all non-small cell lung cancer (NSCLC) patients and approximately 2.8% of resected stage I-III NSCLC patients. Savolitinib is an oral, potent and highly selective type Ib MET inhibitor, which has been shown to be pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Meng, Feng, Chun-Mei, Xia, Da-Qing, Ji, Zi-Mei, Xia, Huai-Ling, Hu, Na-Na, Leng, Zai-Jun, Xie, Wang, Fang, Yuan, Cao, Le-Jie, Zhang, Jun-Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424904/
https://www.ncbi.nlm.nih.gov/pubmed/36052259
http://dx.doi.org/10.3389/fonc.2022.954886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424904/
https://www.ncbi.nlm.nih.gov/pubmed/36052259
http://dx.doi.org/10.3389/fonc.2022.954886

Ejemplares similares